Receptor de Efrina
Os inibidores dos receptores de efrina têm como alvo os receptores Eph, uma família de tirosina quinases receptoras que interagem com ligantes de efrina ligados à membrana. A sinalização de efrina é crucial para o posicionamento celular, a padronização dos tecidos e a angiogênese. A desregulação dessa via está implicada no câncer, em doenças neurodegenerativas e em distúrbios do desenvolvimento. Na CymitQuimica, oferecemos inibidores dos receptores de efrina para apoiar sua pesquisa em biologia do desenvolvimento, oncologia e neurobiologia.
Foram encontrados 25 produtos de "Receptor de Efrina"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
EphA2 agonist 1
CAS:Compound 7bg is a potent, selective EphA2 agonist targeting overexpressed glioblastoma cells.Fórmula:C50H58N12O12Cor e Forma:SolidPeso molecular:1019.07Nuzefatide
CAS:Nuzefatide is a peptide that binds to liver protein receptors.Fórmula:C105H162N32O27S3Cor e Forma:SolidPeso molecular:2400.80ALW-II-49-7
CAS:<p>ALW-II-49-7 is a selective and potent inhibitor of EphB2 kinase with an EC50 value of 40 nM in cell.</p>Fórmula:C21H17F3N4O2Pureza:99.72%Cor e Forma:SoildPeso molecular:414.38SA-PA
SA-PA, a self-assembled intracellular PROTAC leveraging azide-alkyne click chemistry, selectively degrades VEGFR-2, PDGFR-β, and EphB4 proteins within U87 cellsFórmula:C40H32ClF3N10O8Pureza:98%Cor e Forma:SolidPeso molecular:873.19PKMYT1-IN-8
<p>PKMYT1-IN-8 (Compound 137) is an inhibitor of PKMYT1, with an IC50 value of 9 nM. It also inhibits EPHB3, EPHA1, KIT, EPHB1, EPHA2, EPHA3, and EPHB2, exhibiting IC50 values of 1.79, 3.17, 4.29, 6.32, 6.83, 8.10, and 10.9 μM, respectively. Additionally, PKMYT1-IN-8 suppresses the proliferation of cancer cells OVCAR3 with a GI50 of 2.02 μM.</p>Fórmula:C17H16F3N5O2Cor e Forma:SolidPeso molecular:379.336AZ12672857
CAS:<p>AZ12672857 is an inhibitor of EphB4 with IC50 of 1.3 nM.</p>Fórmula:C26H30N8O2Pureza:98.99%Cor e Forma:SolidPeso molecular:486.57UniPR1449
UniPR1449 is an EphA2 receptor antagonist with a KD of 3.8±2.4 μM, which is significant in cancer pathophysiology [1].Pureza:98%Cor e Forma:Odour SolidKYL peptide
CAS:EphA4 inhibitor, Kd 0.8 μM, blocks EphA4-EphrinA5; avoids AβO damage, preserves spines & LTP; long half-life (8-12h), neuroprotective.Fórmula:C74H108N14O17Pureza:98%Cor e Forma:SolidPeso molecular:1465.75AWL-II-38.3
CAS:AWL-II-38.3 is a highly potent EphA3 inhibitor with potent kinase inhibitory activity against EphA3.Cost-effective and quality-assured.Fórmula:C23H18F3N5O3Pureza:99.03% - 99.57%Cor e Forma:SolidPeso molecular:469.42Ref: TM-T38511
1mg81,00€5mg170,00€10mg264,00€25mg543,00€50mg780,00€100mg1.074,00€500mg2.167,00€1mL*10mM (DMSO)177,00€123C4
CAS:123C4 is a potent, selective and competitive agonist of the receptor tyrosine kinase EPHA4 (Ki=0.65 μM)[1].Fórmula:C43H47ClN8O6Pureza:98.94%Cor e Forma:SolidPeso molecular:807.34Ref: TM-TP1561
1mg144,00€5mg311,00€10mg512,00€25mg815,00€50mg1.093,00€100mg1.473,00€1mL*10mM (DMSO)507,00€Ehp-inhibitor-2
CAS:Ehp-inhibitor-2 is an Eph family tyrosine kinase inhibitor targeting Eph receptors.Fórmula:C17H13N5OPureza:97.88%Cor e Forma:SolidPeso molecular:303.32Ref: TM-T5452
2mg35,00€5mg55,00€10mg96,00€25mg146,00€50mg210,00€100mg309,00€200mg444,00€1mL*10mM (DMSO)62,00€NVP-BHG712 isomer
CAS:NVP-BHG712 isomer shows conserved non-bonded binding to EPHA2 and EPHB4.Fórmula:C26H20F3N7OPureza:99.14%Cor e Forma:SolidPeso molecular:503.48Ref: TM-T19487
1mg43,00€2mg56,00€5mg88,00€10mg150,00€25mg259,00€50mg376,00€100mg560,00€1mL*10mM (DMSO)87,00€JI-101
CAS:JI-101 (CGI-1842) is an oral multi-kinase inhibitor that targets VEGFR-2, PDGFR-β, and EphB4.Fórmula:C22H20BrN5O2Pureza:99.41% - 99.97%Cor e Forma:SolidPeso molecular:466.33NVP-BHG712
CAS:NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src andFórmula:C26H20F3N7OPureza:97.32% - 98.63%Cor e Forma:SolidPeso molecular:503.48Ref: TM-T6348
1mg34,00€5mg74,00€10mg105,00€25mg200,00€50mg371,00€100mg557,00€200mg790,00€1mL*10mM (DMSO)84,00€Eph inhibitor 2
CAS:Eph inhibitor 2 is an Eph family tyrosine kinase inhibitor targeting Eph receptors.Fórmula:C18H15N5OPureza:99.01%Cor e Forma:SolidPeso molecular:317.34Ref: TM-T5451
1mg95,00€2mg125,00€5mg188,00€10mg284,00€25mg515,00€50mg742,00€100mg1.035,00€500mg2.080,00€1mL*10mM (DMSO)187,00€Tesevatinib
CAS:Tesevatinib (XL-647) is an oral, multi-targeted tyrosine kinase inhibitor.Cost-effective and quality-assured.Fórmula:C24H25Cl2FN4O2Pureza:97.89% - 98.66%Cor e Forma:SolidPeso molecular:491.39Ref: TM-TQ0166
1mg107,00€2mg156,00€5mg236,00€10mg457,00€25mg750,00€50mg1.026,00€1mL*10mM (DMSO)255,00€KYL acetate(676657-00-4 free base)
EphA4 inhibitor, Kd: 0.8 μM, IC50: 6.34 μM. Protects synapses and spines, maintains LTP. Long half-life: 8-12h. Neuroprotective.Fórmula:C76H112N14O19Pureza:99.75%Cor e Forma:SolidPeso molecular:1525.78Tivozanib
CAS:Tivozanib (KRN951) is an oral VEGFRs 1-3 inhibitor with potential antiangiogenic and cancer-fighting properties.Fórmula:C22H19ClN4O5Pureza:98.08% - 99.67%Cor e Forma:SolidPeso molecular:454.86Ref: TM-T2456
2mg38,00€5mg57,00€10mg79,00€25mg135,00€50mg226,00€100mg405,00€200mg597,00€1mL*10mM (DMSO)63,00€ALW-II-41-27
CAS:ALW-II-41-27 (Eph receptor tyrosine kinase inhibitor), an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.Fórmula:C32H32F3N5O2SPureza:97.01% - 99.52%Cor e Forma:SolidPeso molecular:607.69Ref: TM-T4344
1mg63,00€5mg159,00€10mg236,00€25mg371,00€50mg522,00€100mg713,00€200mg982,00€1mL*10mM (DMSO)216,00€UniPR129
CAS:UniPR129 is a competitive Eph-ephrin antagonist agent that acts by blocking in vitro angiogenesis at low micromolar concentrations.Fórmula:C36H52N2O4Pureza:98%Cor e Forma:SolidPeso molecular:576.81
